Results 171 to 180 of about 106,875 (237)

Deletion of Schizophrenia Susceptibility Gene Ulk4 Leads to Abnormal Cognitive Behaviors via Akt-GSK-3 Signaling Pathway in Mice. [PDF]

Schizophr Bull, 2022
Hu L, Zhou BY, Yang CP, Lu DY, Tao YC, Chen L, Zhang L, Su JH, Huang Y, Song NN, Chen JY, Zhao L, Chen Y, He CH, Wang YB, Lang B, Ding YQ.   +16 more
europepmc   +1 more source

Neurological Functions of the Masterswitch Protein Kinase – Gsk-3 [PDF]

Frontiers in Molecular Neuroscience, 2012
Oksana eKaidanovich-Beilin, Jean-Martin eBeaulieu, Richard Scott Jope, James Robert Woodgett, James Robert Woodgett   +4 more
openaire   +3 more sources

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance

International Journal of Cancer, EarlyView.
What's New? Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor to multiple myeloma, sharing substantial genetic features with overt malignancy. Given evidence implicating autophagy in myeloma risk, this study examined whether genetic variations in autophagy‐related genes influence MGUS susceptibility.
José Manuel Sánchez‐Maldonado, Angelica Macauda, Antonio José Cabrera‐Serrano, Hauke Thomsen, Murat Güler, Rob Ter Horst, Bethany van Guelpen, Pavel Vodicka, Stefano Landi, Subhayan Chattopadhyay, Pelin Ünal, Lucía Ruiz‐Durán, Delphine Casabonne, Hartmut Goldschmidt, Istemi Serin, María Carretero‐Fernández, Elena Cabezudo, Fernando Reyes‐Zurita, Aaron D. Norman, Ramón García‐Sanz, Gabriele Capurso, Per Hoffmann, Ulrika Pettersson‐Kymmer, Francisco Jiménez‐Romera, S. Vincent Rajkumar, Niels Weinhold, Ludmila Vodickova, Christian Langer, Angelika Stein, Abdulkadir Karismaz, Victor Moreno, Markus M. Nöthen, Karl‐Heinz Jöckel, Francesca Tavano, Joaquín Martínez‐López, Shaji K. Kumar, Juan Francisco Gutiérrez‐Bautista, Daniela Basso, Florentin Späth, Yolanda Benavente, Michelle A. T. Hildebrandt, Börge Schmidt, Tereza Sevcikova, Rui Manuel Vieira Reis, Yang Li, Miguel Ángel López‐Nevot, Mihai G. Netea, Daniele Campa, Alyssa Clay‐Gilmour, Susan L Slager, Kari Hemminki, Celine M Vachon, Asta Försti, Federico Canzian, Juan Sainz   +54 more
wiley   +1 more source

GSK-3 Inhibitor 9-ING-41 [PDF]

, 2020
openaire   +1 more source

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

International Journal of Cancer, EarlyView.
What's New? Although patients with melanoma brain metastases (MBM) may benefit from treatment with immune checkpoint inhibitors (ICIs), which are known to improve survival in advanced melanoma, MBM patients have often been excluded from trials evaluating ICIs.
Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler, Peter Mohr, Thomas Sickmann, Pia Dücker, Christoffer Gebhardt, Sebastian Haferkamp, Katharina C. Kähler, Friedegund Meier, Claudia Pföhler, Anca Sindrilaru, Patrick Terheyden, Imke von Wasielewski, Selma Ugurel, Jens Ulrich, Jochen Utikal, Carsten Weishaupt, Dirk Schadendorf   +18 more
wiley   +1 more source

The many faceted role of glycogen synthase kinase-3 (GSK-3) in T cells and cancer immunotherapy. [PDF]

J Cancer Biol
Crespo AR, Luna SG, Moës B, Rodriguez A, Rudd CE.   +4 more
europepmc   +1 more source

Aggregatibacter actinomycetemcomitans Cytolethal Distending Toxin-Induces Cell Cycle Arrest in a Glycogen Synthase Kinase (GSK)-3-Dependent Manner in Oral Keratinocytes. [PDF]

Int J Mol Sci, 2022
Shenker BJ, Walker LP, Zekavat A, Korostoff J, Boesze-Battaglia K.   +4 more
europepmc   +1 more source

GSK-3: New Thoughts on an Old Enzyme

Developmental Biology, 2000
Ferkey, Denise M., Kimelman, David
openaire   +2 more sources

Prediction of the individual risk for the development of brain metastases in patients with non‐oncogene‐addicted non‐small cell lung cancer: Real‐world data from the German prospective CRISP registry (AIO‐TRK‐0315)

International Journal of Cancer, EarlyView.
What's New? Estimating the risk of developing brain metastases may enable earlier diagnosis and treatment, potentially reducing morbidity and mortality. Using the prospective CRISP lung cancer registry, the authors developed and validated a point‐based classifier for the risk of developing first brain metastases in patients with advanced or metastatic ...
Fabian Acker, Katharina Wenger, Martin Reck, Cornelius F. Waller, Petra Hoffknecht, Andre Bethge, Arnd Nusch, Marcel Reiser, Christiane Bernhardt, Michael Bendel, Carolin Lennartz, Annette Fleitz, Martina Jänicke, Paula Ludwig, Annika Groth, Frank Griesinger, Michael Thomas, Wilfried E. E. Eberhardt, Martin Sebastian, for the CRISP Registry Group   +19 more
wiley   +1 more source